The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis
暂无分享,去创建一个
J. Ertle | J. Trebicka | A. Berzigotti | I. Gashaw | T. Reiberger | Rose-Marie Swallow | Andrea Tomisser